Improvement of therapeutic index against immune checkpoint inhibitors using combination therapy comprising PHY906 extract, scutellaria baicalensis extract or compounds from these extracts

Through a combination therapy combining PHY906 extract and anti-immune checkpoint inhibitors, the gastrointestinal side effects of anti-immune checkpoint inhibitors are solved when treating tumors, and the treatment index and anti-tumor activity are improved, especially suitable for melanoma and other Types of cancer.

CN118903271APending Publication Date: 2024-11-08YALE UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411104708.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2016-05-23
Filing Date
2017-05-23
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing anti-immune checkpoint inhibitors, such as PD1 and PD-L1 inhibitors, are used to treat tumors often cause gastrointestinal side effects such as nausea, diarrhea, fatigue and vomiting, and their treatment index is insufficient, making it difficult to effectively inhibit tumor growth.

Method used

Using a combination therapy containing PHY906 extract, Scutellaria baicalensis extract or its compounds, combined with anti-immune checkpoint inhibitors such as anti-PD1, anti-PD-L1 and anti-CTLA4 for the treatment of melanoma and other types of cancers, by oral administration Herbal compositions reduce or eliminate gastrointestinal side effects of immune checkpoint inhibitors and enhance therapeutic effects.

Benefits of technology

Effectively reduces the gastrointestinal side effects of anti-immune checkpoint inhibitors, and improves the treatment index of tumors and enhances anti-tumor activity, especially in the treatment effects of melanoma, non-small cell lung cancer, renal cell carcinoma and other types. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903271A_ABST
    Figure CN118903271A_ABST
Patent Text Reader

Abstract

The present invention relates to a combination therapy comprising a PHY906 extract, a Scutellaria baicalensis extract or a compound therefrom. The present invention provides methods of treating melanoma and other cancers comprising administering to a subject a therapeutically effective amount of a herbal extract of PHY906 or Scutellaria baicalensis, a portion thereof, or any active chemical present in the herbal extract or portion thereof, and one or more immune checkpoint inhibitors. In certain embodiments, the method further comprises administering at least one herbal extract of at least one herbal selected from the group consisting of licorice, Chinese herbaceous peony and jujube, a portion thereof, or any active chemical present in the herbal extract or a portion thereof. The methods of the invention are useful for the treatment of cancers such as melanoma, non-small cell lung cancer, renal cell carcinoma, liver cancer, colon cancer, urothelial bladder cancer and pancreatic cancer. In certain embodiments, administration of the herbal extracts of the invention counteracts one or more gastrointestinal side effects of the immune checkpoint inhibitor and / or increases its therapeutic index against cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application. The application date of the original application is May 23, 2017, the application number is 201780040034.5, and the name of the invention is "Improving the therapeutic index of resistance to immune checkpoint inhibitors using combination therapy containing PHY906 extract, Scutellaria baicalensis extract or compounds derived from these extracts."

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority under 35 USC §119(e) to U.S. Provisional Application No. 62 / 340,164, filed May 23, 2016, which is incorporated herein by reference in its entirety.

[0004] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0005] This invention was made with government support under CA154295-01A1 awarded by the National Institutes of Health (NIH). The government has certain rights in this invention. Technical Field

[0006] The present application relates to combination therapies comprising PHY906 extract, Scutellaria baicalensis extract, or compounds derived from these extracts and to improving the therapeutic index of resistance to immune checkpoint inhibitors using combination therapies comprising PHY906 extract, Scutellaria baicalensis extract, or compounds derived from these extracts. Background Art

[0007] Many tumors can evade immune system responses by upregulating co-inhibitory pathways, also known as immune checkpoints. The PDL-PD1 pathway is one such immune checkpoint. When cytotoxic T cells (CD8 positive) approach tumor cells, they secrete interferon-γ (IFNγ), which upregulates PD-L1 protein expression on the surface of tumor cells. The interaction between the PD-L1 protein on the tumor cell membrane and the PD1 protein on the T cell membrane can inactivate T cell killing, so that the tumor is not eliminated by T cells. For example, inhibition of the PDL-PD1 pathway has been shown to be effective in inhibiting tumor cell growth in non-small cell lung cancer, melanoma, and renal cell carcinoma. Unfortunately, the PD1 and PD-L1 inhibitors approved by the US FDA (such as but not limited to pembrolizumab) Nivolumab Durvalumab (MEDI4736), Atezolizumab and ipilimumab ) are also known to cause nausea, diarrhea, fatigue, colitis, and vomiting, particularly in combination with anti-CTLA4 (see, e.g., Figure 4 ).

[0008] PHY906 is an herbal blend extract based on the Huangqin Tang herbal blend, first described in Chinese literature 1800 years ago and has been used to treat gastrointestinal symptoms. PHY906 consists of four herbs: Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P), and Ziziphus jujuba (Z). PHY906 is currently manufactured under cGMP (Current Good Manufacturing Practice). In clinical trials, PHY906 has shown to enhance the therapeutic index of chemotherapy against cancer.

[0009] Therefore, there is an unmet need in the art for new compositions and methods for treating tumors by inhibiting the PDL-PD1 pathway. In certain embodiments, such methods should enhance the therapeutic index of PDL-PD1 pathway inhibitors without compromising the anti-cancer activity of anti-immune checkpoint therapy. The present invention meets this unmet need. Summary of the invention

[0010] The present invention includes a kit comprising one or more immune checkpoint inhibitors and at least one herbal composition selected from the group consisting of: (a) an herbal extract of Scutellaria baicalensis (S), a portion thereof or any active chemical substance present in the herbal extract or a portion thereof; (b) an herbal extract PHY906 (which comprises an herbal extract of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Ziziphus jujuba (Z)), a portion thereof or any active chemical substance present in the herbal extract or a portion thereof; (c) an herbal extract comprising an extract of S, a portion thereof or any active chemical substance present in the herbal extract or a portion thereof; and (d) an herbal extract (comprising a combination of S, G, P and Z), a portion thereof or any active chemical substance present in the herbal extract or a portion thereof.

[0011] In certain embodiments of the kit of the present invention, (a) or (c) further comprises an herbal extract, a portion thereof, or any active chemical substance present in an herbal extract or a portion thereof, wherein the herbal extract is from at least one herb selected from Licorice (G), Peony (P) and Jujube (Z).

[0012] In certain embodiments, the immune checkpoint inhibitor is selected from anti-PD1, anti-PD-L1 and anti-CTLA4. In other embodiments, the immune checkpoint inhibitor is selected from Ipilimumab, Pembrolizumab, Nivolumab, Durvalumab and Atezolizumab.

[0013] In certain embodiments, the kit further comprises one or more pharmaceutically acceptable carriers.

[0014] The present invention further provides a method of treating cancer in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of at least one herbal composition of the present invention and one or more immune checkpoint inhibitors, wherein the cancer is at least one selected from melanoma, non-small cell lung cancer, renal cell carcinoma, liver cancer, colon cancer, urothelial bladder cancer, and pancreatic cancer. In certain embodiments, the cancer is melanoma.

[0015] In certain embodiments, the immune checkpoint inhibitor is selected from anti-PD1, anti-PD-L1 and anti-CTLA4. In other embodiments, the immune checkpoint inhibitor is selected from ipilimumab, pembrolizumab, nivolumab, durvalumab and atezolizumab.

[0016] In certain embodiments, the therapeutically effective amount of the herbal composition minimizes or eliminates gastrointestinal side effects of one or more immune checkpoint inhibitors selected from nausea, vomiting, fatigue, colitis, and diarrhea.

[0017] In certain embodiments, the herbal composition is orally administered to a subject. In other embodiments, the herbal composition is orally administered to a subject in a form selected from pills, tablets, capsules, soups, teas, concentrates, lozenges, liquids, drops, and gelcaps.

[0018] In certain embodiments, the therapeutically effective amount of the herbal composition is about 20 mg / day to about 2 g / day. In other embodiments, the therapeutically effective amount of the herbal composition is about 1,600 mg / day. In other embodiments, the herbal composition is administered twice daily.

[0019] In certain embodiments, the herbal composition is administered twice daily for about one to about two weeks, followed by a break in treatment for at least one week.

[0020] In certain embodiments, the herbal composition is administered at a time selected from before, simultaneously with, and after administration of one or more immune checkpoint inhibitors to the subject.

[0021] In certain embodiments, the subject is a mammal. In other embodiments, the mammal is a human. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The following detailed description of specific embodiments of the present invention will be better understood when read in conjunction with the accompanying drawings. For the purpose of illustrating the present invention, specific embodiments are shown in the accompanying drawings. However, it should be understood that the present invention is not limited to the precise arrangements and means of the embodiments shown in the accompanying drawings.

[0023] Figures 1A-1G Depicted are graphs and tables reporting the effects of PHY906 and anti-PD-L1 on the growth of subcutaneously implanted B16 melanoma tumors in B6 mice. Administration was as follows: PHY906 (500 mg / kg, twice daily (bid), Day 0 to Day 5) and / or anti-PD-L1 (150 μg per animal, intraperitoneal injection (IP), Day 0 and Day 4). Figures 1A-1E Relative tumor size after various treatment regimens is shown. Figure 1A A summary of four potential treatment options is shown. Figure 1B A control experiment is shown. Figure 1C Treatment with PHY906 alone is shown. Figure 1D Treatment with anti-PD-L1 alone is shown. Figure 1E Treatment with PHY906 and anti-PD-L1 is shown. Figure 1F It is shown Figures 1A-1E The significance of the data reported in the table is shown in Figure 2, where P < 0.05 indicates a significant result. Figure 1G It is shown Figures 1B-1F Figure 2 shows the relative weight changes for each treatment regimen reported in .

[0024] Figures 2A-2F Depicted are graphs reporting the effects of PHY906 and anti-PD-L1 on the growth of brain-implanted B16 melanoma tumors in B6 mice. Figure 2A Depicted are graphs showing the survival of mice bearing B16 brain tumors after treatment with control, PHY906 (500 mg / kg, twice daily, on days 0 and 5), anti-PD-L1 (150 μg per animal, ip, on days 0 and 4), or both PHY906 and anti-PD-L1. Figure 2B is a graph showing tumor luciferase intensity (measured using luciferase imaging) after treatment with control. Figure 2C is a graph showing tumor luciferase intensity (measured using luciferase imaging) after treatment with PHY906. Figure 2D is a graph showing tumor luciferase intensity (measured using luciferase imaging) after treatment with anti-PD-L1. Figure 2E is a graph showing tumor luciferase intensity (measured using luciferase imaging) after treatment with PHY906 and anti-PD-L1. Figure 2F Depicted showing Figure 2B-2EFigure 2 shows the change in body weight (grams) for each treatment regimen reported in .

[0025] Figure 3 Depicted are graphs showing the effects of PHY906 (500 mg / kg, twice daily on days 0, 1, 2, and 3), anti-PD-L1 (150 μg per animal, ip, on day 0), PHY906 + anti-PD-L1, and Scutellaria baicalensis (S, 500 mg / kg, twice daily on days 0, 1, 2, and 3) + anti-PD-L1 on the growth of subcutaneously implanted B16 melanoma tumors in B6 mice.

[0026] Figure 4 is a table showing gastrointestinal side effects of approved autoimmune checkpoint therapeutics (adapted from Larkin, et al., 2005, N. Engl. Med. 373:23-34).

[0027] Figure 5 is a table showing non-hematologic toxicity of irinotecan-based IFL chemotherapy in patients with advanced colorectal cancer (adapted from Kummar, et al., 2011, Clin. Colorectal Cancer 10(2):85-96).

[0028] Figures 6A-6D is a graph reporting the in vivo effects of PHY906 alone and in combination with anti-PD-L1, anti-PD1, and anti-CTLA4 antibodies against B16 melanoma. Figures 6A-6C In this study, PHY906 was administered at a dose of 500 mg / kg twice daily and, where appropriate, anti-PD-L1 ( Fig. 6A , 150 μg / animal), anti-PD1 ( Figure 6B , 150 μg / animal) and anti-CTLA4 ( Figure 6C , 300 μg / animal) was administered once every 3 days. Fig.6D In the experiment, PHY906 was administered twice daily at a dose of 500 mg / kg or 1 g / kg, and anti-PD1 (150 μg / animal) and anti-CTLA4 (300 μg / animal) were administered every 3 days as described above.

[0029] Figures 7A-7E is a graph reporting the effect of PHY906 alone and in combination with anti-PD1 antibody on the size of Hepa 1-6 mouse hepatic adenocarcinoma tumors. Fig. 7A In the experiment, PHY906 was administered twice a day at a dose of 500 mg / kg for 7 days. Anti-PD1 antibody was administered once at a dose of 200 μg / mouse at the beginning of the experiment. Figure 7B Shows the Fig. 7A The changes in tumor size averaged across multiple trials for each treatment regimen. Figure 7Cand 7D Is the report with Fig. 7A Figure 2 shows a similar experiment in which PHY906 was administered twice daily at a dose of 500 mg / kg for 7 days and anti-PD1 antibody was administered once at the beginning of the experiment at a dose of 70 μg / mouse or 200 μg / mouse. Fig. 7E Shows the Figure 7C-7D The changes in tumor size averaged across multiple trials for each treatment regimen.

[0030] Fig. 8A and 8B is a graph reporting the effect of PHY906 alone and in combination with anti-PD1 antibody on CMT-167 non-small cell lung cancer tumor size. Fig. 8A In this study, PHY906 was administered at a dose of 500 mg / kg twice a day for 7 days, and anti-PD1 antibody was administered once at a dose of 200 μg / mouse at the beginning of the experiment. Figure 8B Shows the Fig. 8A The changes in tumor size averaged across multiple trials for each treatment regimen. DETAILED DESCRIPTION

[0031] In one aspect, the present invention relates to the unexpected discovery that any of the following compositions or any combination thereof can be used in combination with one or more immune checkpoint inhibitors for the treatment of melanoma and other cancers: (a) an herbal extract of Scutellaria baicalensis (S), a portion thereof, or any active chemical present in an herbal extract or a portion thereof; (b) an herbal extract PHY906 (which comprises an herbal extract of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P), and Ziziphus jujuba (Z)), a portion thereof, or any active chemical present in an herbal extract or a portion thereof; (c) an herbal extract (an extract comprising S), a portion thereof, or any active chemical present in an herbal extract or a portion thereof; and (d) an herbal extract (combination comprising S, G, P, and Z), a portion thereof, or any active chemical present in an herbal extract or a portion thereof. In certain embodiments, these herbal extracts or their isolated portions or active chemical present therein can be administered simultaneously or in combination with an immune checkpoint inhibitor to a subject suffering from cancer. In certain embodiments, the herbal extract comprises an aqueous extract, an alcohol extract, an acid extract, an alkaline extract, or any combination thereof.

[0032] The present invention also relates to a kit comprising a pharmaceutical composition comprising one or more immune checkpoint inhibitors and any of the following compositions or any combination thereof: (a) an herbal extract of Scutellaria baicalensis (S), a portion thereof or any active chemical substance present in an herbal extract or a portion thereof; (b) an herbal extract PHY906 (an herbal extract comprising Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Ziziphus jujuba (Z)), a portion thereof or any active chemical substance present in an herbal extract or a portion thereof; (c) an herbal extract (an extract comprising S), a portion thereof or any active chemical substance present in an herbal extract or a portion thereof; and (d) an herbal extract (combination comprising S, G, P and Z), a portion thereof or any active chemical substance present in an herbal extract or a portion thereof.

[0033] definition

[0034] As used herein, each of the following terms has the meaning associated with it in this section.

[0035] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, exemplary methods and materials are described.

[0036] Generally, the nomenclature used herein and the laboratory procedures in pharmacology, natural product chemistry, and organic chemistry are those well known and commonly used in the art.

[0037] As used herein, the articles "a" and "an" refer to one or to more than one (ie, to at least one) of the grammatical object of the article. For example, "an element" means one element or more than one element.

[0038] As used herein, the term "cancer" is defined as a disease characterized by the rapid and uncontrolled growth of abnormal cells. Cancer cells can spread locally or through the bloodstream and lymphatic system to other parts of the body. Examples of various cancers include, but are not limited to, bone cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, kidney cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, etc.

[0039] In one aspect, the terms "co-administered" and "co-administration" with respect to a subject refer to the administration of compounds and / or compositions of the invention to a subject and compounds and / or compositions that may also treat or prevent a disease or condition contemplated herein. In certain embodiments, the co-administered compounds and / or compositions are administered alone or in any combination as part of a monotherapy approach. The co-administered compounds and / or compositions can be formulated as mixtures of solids and liquids, and as solutions, in any combination, under various solid, gel, and liquid formulations.

[0040] As used herein, the term "extract" refers to a concentrated preparation or solution of a compound or drug derived from a naturally occurring source such as an herb or other plant material. The extract can be prepared by a number of methods, including soaking the herb in a solution, or drying and grinding the herb into a powder and dissolving the powder in a solution. After a certain amount of the desired compound is dissolved in the solution, the extract can be further concentrated by removing a portion of the solvent. The extract can also be filtered or centrifuged to remove any solid matter from the solution.

[0041] As used herein, the phrase "inhibit" refers to a reduction in the expression, stability, function or activity of a molecule, reaction, interaction, gene and / or protein, a measurable amount or complete prevention. Inhibitors are compounds that, for example, bind, partially or completely block stimulation, reduce, prevent, delay activation, inactivate, desensitize or downregulate the stability, expression, function and activity of a protein or gene, such as antagonists.

[0042] As used herein, the term "pharmaceutical composition" or "composition" refers to a mixture of at least one compound useful in the present invention and a pharmaceutically acceptable carrier. A pharmaceutical composition facilitates administration of a compound to a subject.

[0043] As used herein, the term "pharmaceutically acceptable" refers to a material such as a carrier or diluent that does not abrogate the biological activity or properties of the compounds useful in the present invention and is relatively nontoxic, i.e., a material that can be administered to a subject without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition contained therein.

[0044] As used herein, the term "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersant, suspending agent, diluent, excipient, thickener, solvent or encapsulating material, which is involved in delivering or transporting a compound useful in the present invention within a subject or delivering or transporting a compound useful in the present invention to a subject so that it can perform its intended function. Typically, such constructs are delivered or transported from one organ or part of the body to another organ or part of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation, including the compounds useful in the present invention, and not harmful to the subject. Some examples of materials that can be used as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, such as propylene glycol; polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; surfactants; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffer solution; and other nontoxic compatible substances used in pharmaceutical formulations. As used herein, "pharmaceutically acceptable carrier" also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, etc. that are compatible with the activity of the compounds useful in the present invention and are physiologically acceptable to the subject. Supplementary active compounds may also be incorporated into the composition. A "pharmaceutically acceptable carrier" may further include a pharmaceutically acceptable salt of a compound useful in the present invention. Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the present invention are known in the art and are described, for example, in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.

[0045] As used herein, the term "pharmaceutically acceptable salt" refers to a salt of the administered compound prepared from pharmaceutically acceptable non-toxic acids and bases, including inorganic acids, inorganic bases, organic acids, inorganic bases, solvates, hydrates and inclusion compounds thereof. Suitable pharmaceutically acceptable acid addition salts can be prepared from inorganic or organic acids. Examples of inorganic acids include sulfates, bisulfates, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, carbonic acid, sulfuric acid and phosphoric acid (including hydrogen phosphate and dihydrogen phosphate). Suitable organic acids can be selected from aliphatic, alicyclic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic acid classes of organic acids, examples of which include formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, gluconic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, glucuronic acid, maleic acid, fumaric acid, pyruvic acid, aspartic acid, glutamic acid, benzoic acid, anthranilic acid, 4-hydroxybenzoic acid, phenylacetic acid, mandelic acid, pamoic acid (pamoic acid), methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, pantothenic acid, trifluoromethanesulfonic acid, 2-hydroxyethylsulfonic acid, p-toluenesulfonic acid, p-aminobenzenesulfonic acid, cyclohexylaminosulfonic acid, stearic acid, alginic acid, β-hydroxybutyric acid, salicylic acid, galactaric acid and galacturonic acid. Suitable pharmaceutically acceptable base addition salts of the compounds of the present invention include, for example, metal salts, including alkali metal, alkaline earth metal and transition metal salts such as, for example, calcium, magnesium, potassium, sodium and zinc salts. Pharmaceutically acceptable base addition salts also include organic salts made from basic amines, for example, N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts can be prepared from the corresponding compounds by reacting, for example, an appropriate acid or base with the compound.

[0046] The terms "pharmaceutically effective amount" and "effective amount" refer to a non-toxic but sufficient amount of an agent to provide a desired biological result. The result can be a reduction and / or alleviation of the signs, symptoms or causes of a disease or condition, or any other desired change in a biological system. One of ordinary skill in the art can determine the appropriate effective amount in any individual case using routine experimentation. "Pharmaceutical formulation" also refers to the carrier, solvent, excipient (or multiple) and / or salt that must be compatible with the active ingredient of the formulation (e.g., a compound of the invention). One of ordinary skill in the art will appreciate that the terms "pharmaceutical formulation" and "pharmaceutical composition" are generally interchangeable, and they are used as such for the purposes of this application.

[0047] As used herein, the term "PHY906" refers to an herbal composition comprising Glycyrrhiza uralensis (G), Peony Root (P), Scutellaria baicalensis Georgi (S) and Ziziphus jujuba (Z). PHY906 may refer to, for example, a specific composition comprising S, G, P and Z in a ratio of 3:2:2:2 prepared under standard operating procedures.

[0048] As used herein, the terms "prevent," "prevention," or "preventing" refer to any method that partially or completely prevents or delays the onset of one or more symptoms or features of a disease, disorder, and / or condition (e.g., cancer). Prevention results in clinical symptoms of a disease state not developing in a subject who may be exposed to or susceptible to the disease state but has not yet experienced or displayed symptoms of the disease state, i.e., inhibiting the onset of the disease. Prevention can be performed on subjects who do not show signs of the disease, disorder, and / or condition.

[0049] As used herein, the terms "subject," "patient," or "individual" contemplated for administration include, but are not limited to, humans (i.e., males or females of any age group, such as pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or elderly)) and / or other primates (e.g., cynomolgus monkeys, rhesus monkeys); mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and / or dogs; and / or birds, including commercially relevant birds such as chickens, ducks, geese, quail, and / or turkeys.

[0050] As used herein, the term "therapeutically effective amount" is an amount of a compound of the invention that, when administered to a patient, treats, minimizes and / or alleviates the symptoms of a disease or condition. The amount of a compound of the invention that constitutes a "therapeutically effective amount" will vary depending on the compound, the disease state and its severity, the age of the patient to be treated, etc. A therapeutically effective amount can be routinely determined by one of ordinary skill in the art based on his own knowledge and this disclosure.

[0051] As used herein, the term "treatment" or "treat" is defined as the application or administration of a therapeutic agent (i.e., a compound useful in the invention (alone or in combination with another agent)) to a subject, or the application or administration of a therapeutic agent to an isolated tissue or cell line from a subject (e.g., for diagnostic or ex vivo use), who has cancer, a symptom of cancer, or a likelihood of developing cancer, for the purpose of curing, curing, alleviating, mitigating, altering, remedying, alleviating, improving, or affecting the cancer, a symptom of cancer, or the likelihood of developing cancer. These treatments can be specifically tailored or modified based on the knowledge gained from the field of pharmacogenomics.

[0052] Range: Throughout this disclosure, various aspects of the invention may be presented in range format. It should be understood that descriptions in range format are merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Therefore, descriptions of ranges should be considered to specifically disclose all possible subranges and individual numerical values ​​within the range. For example, a description of a range such as 1 to 6 should be considered to specifically disclose subranges such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., as well as individual and partial numbers within the range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.

[0053] The following abbreviations are used in this article:

[0054] cGMP Current Good Manufacturing Practice

[0055] G Licorice, also known as Chinese Licorice

[0056] IFNγInterferon-γ

[0057] P Paeonia lactiflora, also known as Chinese peony

[0058] S Scutellaria baicalensis, also known as Baikal skullcap or scute

[0059] Z jujube, also known as red dates or Chinese dates

[0060] Composition

[0061] The present invention relates to compounds and compositions for treating cancer. In certain embodiments, the compositions of the present invention can be used to treat melanoma and other cancers, reducing gastrointestinal toxicity caused by anti-PD-L1, anti-PD1 or anti-CTLA4 without affecting their anti-tumor activity.

[0062] In certain embodiments, the composition comprises an herbal extract of Scutellaria baicalensis (S), a fraction thereof, or any active chemical substance present in the herbal extract or a fraction thereof.

[0063] In certain embodiments, the composition comprises the herbal extract PHY906 comprising herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P), and Ziziphus jujuba (Z), a fraction thereof, or any active chemical substance present in the herbal extract or a fraction thereof.

[0064] In certain embodiments, the composition comprises an herbal extract (an extract comprising S), a fraction thereof, or any active chemical substance present in an herbal extract or a fraction thereof.

[0065] In certain embodiments, the composition comprises an herbal extract (comprising a combination of S, G, P, and Z), a portion thereof, or any active chemical present in an herbal extract or a portion thereof. In other non-limiting embodiments, the composition comprises an herbal extract (comprising a combination of S, G, P, and Z), a portion thereof, or any active chemical present in an herbal extract or a portion thereof, wherein the ratio of herbs S, G, P, and Z is about 3:2:2:2. In yet another non-limiting embodiment, the herbal extract is PHY906.

[0066] In certain embodiments, the composition comprises an herbal extract (comprising a combination of G, P and Z), a fraction thereof, or any active chemical substance present in an herbal extract or a fraction thereof.

[0067] In certain embodiments, the compositions comprise one or more immune checkpoint inhibitors.

[0068] In certain embodiments, the composition further comprises one or more pharmaceutically acceptable carriers.

[0069] In certain embodiments, the one or more immune checkpoint inhibitors are selected from anti-PD1, anti-PD-L1 and anti-CTLA4. In other embodiments, the immune checkpoint inhibitors are selected from ipilimumab, which targets CTLA4. Pembrolizumab targeting PD1 and nivolumab and durvalumab and atezolizumab, which target PD-L1

[0070] Treatment

[0071] The present invention includes a method for treating cancer in a subject, the method including administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof. In certain embodiments, the method includes administering to the subject at least one selected from: (a) herbal extract of Scutellaria baicalensis (S), its part or any active chemical present in herbal extract or its part; (b) herbal extract PHY906 (it includes herbal extracts of Scutellaria baicalensis (S), Licorice (G), Peony (P) and Jujube (Z)), its part or any active chemical present in herbal extract or its part; (c) herbal extract (it includes extract of S), its part or any active chemical present in herbal extract or its part; and (d) herbal extract (combination of S, G, P and Z), its part or any active chemical present in herbal extract or its part. In other embodiments, the method includes administering one or more immune checkpoint inhibitors to the subject together.

[0072] In certain embodiments, one or more immune checkpoint inhibitors are selected from anti-PD1, anti-PD-L1 and anti-CTLA4. In other embodiments, immune checkpoint inhibitors are selected from but not limited to ipilimumab targeting CTLA4. Pembrolizumab targeting PD1 and nivolumab and durvalumab and atezolizumab, which target PD-L1

[0073] In certain embodiments, one or more herbal extracts are orally administered to a subject. In other embodiments, one or more herbal extracts are administered in one or more forms selected from pills, tablets, capsules, soups, teas, concentrates, lozenges, liquids, drops, and gelatin capsules.

[0074] In certain embodiments, the therapeutically effective amount of one or more herbal extracts is from about 20 mg / day to about 2 g / day, in certain embodiments from about 100 mg / day to about 2 g / day, and in other embodiments about 1.6 g / day.

[0075] In certain embodiments, the herbal extract of the present invention may be administered twice daily at a dosage of about 800 mg (i.e., 800 mg twice daily or 1,600 mg / day). In certain embodiments, the herbal extract is administered once or twice daily for about 1 to about 2 weeks. In certain embodiments, the herbal extract is administered for about 1 to about 2 weeks, followed by a break in treatment for one or more weeks.

[0076] In certain embodiments, the therapeutically effective amount of the herbal extract counteracts one or more gastrointestinal side effects of the immune checkpoint inhibitor. In certain non-limiting embodiments, the side effect is at least one selected from nausea, vomiting, fatigue, colitis, and diarrhea.

[0077] In certain embodiments, the cancer is at least one selected from, but not necessarily limited to, melanoma, non-small cell lung cancer, renal cell carcinoma, liver cancer, colon cancer, urothelial bladder cancer, and pancreatic cancer.

[0078] In certain embodiments, herbal extracts and one or more immune checkpoint inhibitors exhibit a synergistic effect. In certain embodiments, when administered as part of the methods of the present invention, the therapeutically effective amount of the immune checkpoint inhibitor is lower than when administered alone. In other embodiments, when administered as part of the methods of the present invention, the effective course of treatment with immune checkpoint inhibitors is shorter than when administered alone. In yet other embodiments, when administered as part of the methods of the present invention, the tumor shrinkage and / or tumor suppression effect of the immune checkpoint inhibitor is greater than when administered alone.

[0079] In certain embodiments, the subject is a mammal. In other embodiments, the subject is a human.

[0080] Administration / dosage / formulation

[0081] The administration regimen may influence what constitutes an effective amount. The therapeutic formulation may be administered to the subject before or after the onset of the disease or condition contemplated by the present invention. In addition, several separate doses and staggered doses may be administered daily or sequentially, or the doses may be infused continuously, or may be bolus injections. In addition, the dosage of the therapeutic formulation may be increased or decreased proportionally, as indicated by the exigencies of the therapeutic or preventive situation.

[0082] The composition of the present invention is administered to a patient, preferably a mammal, more preferably a human, and can be carried out using known procedures at a dose and time period effective to treat the disease or condition considered by the present invention. The effective amount of the therapeutic compound required to achieve a therapeutic effect may vary according to factors such as the state of the patient's disease or condition; the patient's age, sex and weight; and the ability of the therapeutic compound to treat the disease or condition considered by the present invention. The dosage regimen can be adjusted to provide the best therapeutic response. For example, several divided doses may be given per day, or the dose may be reduced proportionally, as indicated by the urgency of the treatment situation. A non-limiting example of an effective dosage range for the therapeutic compound of the present invention is between about 1 and 1,000 mg / kg body weight / day. A pharmaceutical composition useful for practicing the present invention may be administered to deliver a dose between 1 ng / kg / day and 100 mg / kg / day. One of ordinary skill in the art will be able to study the relevant factors and determine the effective amount of the therapeutic compound without undue experimentation.

[0083] Actual dosage levels of the active ingredients in the pharmaceutical compositions of the invention may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

[0084] In particular, the selected dosage level will depend upon a variety of factors including the activity of the particular compound employed, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds or materials used in combination with the compound, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

[0085] A doctor (e.g., physician or veterinarian) with ordinary skills in the art can easily determine and prescribe the effective amount of the desired pharmaceutical composition. For example, a physician or veterinarian can start the dosage of the compound of the present invention used in the pharmaceutical composition at a level lower than that required to achieve the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved.

[0086] In a specific embodiment, it is advantageous to formulate the compound in dosage unit form for ease of administration and uniformity of dosage. As used herein, dosage unit form refers to physically discrete units suitable as unitary dosages for patients to be treated; each unit containing a predetermined quantity of the therapeutic compound calculated to produce the desired therapeutic effect together with the required pharmaceutical carrier. The dosage unit form of the present invention is dictated by and directly dependent on (a) the unique characteristics of the therapeutic compound and the specific therapeutic effect to be achieved, and (b) the limitations inherent in the art of formulating / preparing such therapeutic compounds for the treatment of the diseases or conditions contemplated by the present invention.

[0087] In certain embodiments, one or more pharmaceutically acceptable excipients or carriers are used to prepare the composition of the present invention. In other embodiments, the pharmaceutical composition of the present invention comprises a therapeutically effective amount of the compound of the present invention and a pharmaceutically acceptable carrier. In yet other embodiments, the compound of the present invention is the only bioactive agent in the composition (i.e., capable of treating cancer). In yet other embodiments, the compound of the present invention is the only bioactive agent in the composition (i.e., capable of treating cancer).

[0088] The carrier can be a solvent or dispersion medium, which contains, for example, water, ethanol, polyols (for example, glycerol, propylene glycol and liquid polyethylene glycol, etc.), suitable mixtures thereof, and vegetable oils. For example, by using a coating such as lecithin, by maintaining the required particle size in the case of dispersion and by using a surfactant, suitable fluidity can be maintained. Prevention of microbial effects can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, it is preferred to include isotonic agents in the composition, for example, sugar, sodium chloride or polyols such as mannitol and sorbitol. By including an agent that delays absorption in the composition, for example, aluminum monostearate or gelatin, the extended absorption of injectable compositions can be achieved.

[0089] In certain embodiments, the compositions of the present invention are administered to patients in a dosage range of one to five or more times per day. In other embodiments, the compositions of the present invention are administered to patients in a dosage range including but not limited to once a day, once every two days, once every three days to once a week and once every two weeks. It is apparent to those skilled in the art that the frequency of administration of the various combination compositions of the present invention varies from individual to individual, depending on many factors, including but not limited to age, disease or illness to be treated, sex, overall health and other factors. Therefore, the present invention should not be construed as being limited to any specific dosage regimen, and all other factors of the patient are considered by attending physical examination to determine the precise dosage and composition given to any patient.

[0090] The range of the compounds and / or compositions of the present invention for administration can be from about 1 mg to about 10,000 mg, from about 20 mg to about 9,500 mg, from about 40 mg to about 9,000 mg, from about 75 mg to about 8,500 mg, from about 150 mg to about 7,500 mg, from about 200 mg to about 7,000 mg, from about 400 mg to about 6,000 mg, from about 500 mg to about 5,000 mg, from about 750 mg to about 4,000 mg, from about 1,000 mg to about 3,000 mg, from about 1,000 mg to about 2,500 mg, from about 20 mg to about 2,000 mg, and any and all whole or partial increments therebetween. In certain embodiments, the dosage of the compounds and / or compositions of the present invention is about 800 mg.

[0091] In certain embodiments, the invention relates to packaged pharmaceutical compositions comprising a container holding a therapeutically effective amount of a compound of the invention, alone or in combination with a second agent; and instructions for using the compound to treat, prevent, or reduce one or more symptoms of a disease or condition contemplated by the invention.

[0092] The preparation can be mixed with conventional excipients, which are pharmaceutically acceptable organic or inorganic carrier materials suitable for oral, parenteral, nasal, intravenous, subcutaneous, enteral or any other suitable administration known in the art. The pharmaceutical preparation can be sterilized and, if necessary, can be mixed with adjuvants, for example, lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring agents, flavoring agents and / or aromatic substances, etc. They can also be combined with other active agents as required.

[0093] The administration route of any composition of the present invention includes oral, nasal, rectal, vaginal, parenteral, buccal, sublingual or topical. The compounds used in the present invention can be formulated for administration by any suitable route, such as oral or parenteral, for example, transdermal, transmucosal (e.g., sublingual, lingual, (through) oral, (through) urethral, ​​vaginal (e.g., vaginal or perivaginal), nasal (intra) and (through) rectal), intravesical, intrapulmonary, intraduodenal, intragastric, intrathecal, subcutaneous, intramuscular, intradermal, intraperitoneal, intraarterial, intravenous, intrabronchial, inhalation and topical administration.

[0094] Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gelcaps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, sera, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration, etc. It should be understood that the formulations and compositions useful in the present invention are not limited to the specific formulations and compositions described herein.

[0095] Oral administration

[0096] For oral use, soups, teas, concentrates, tablets, lozenges, liquids, drops, suppositories or capsules, caplets and gelatin capsules are particularly suitable. Compositions intended for oral use can be prepared according to any method known in the art, and such compositions may contain one or more agents selected from inert, pharmaceutically non-toxic excipients suitable for preparing tablets. Such excipients include, for example, inert diluents such as lactose; granulating and disintegrants such as corn starch; binders such as starch; and lubricants such as magnesium stearate. Tablets can be uncoated, or they can be coated by known techniques to elegantly (elegance) or delay the release of the active ingredient. Preparations for oral use can also be presented as hard gelatin capsules, in which the active ingredient is mixed with an inert diluent.

[0097] For oral administration, the compounds of the invention may be in tablet or capsule form, prepared by conventional methods with pharmaceutically acceptable excipients such as: binders (e.g., polyvinyl pyrrolidone, hydroxypropyl cellulose or hydroxypropyl methylcellulose); fillers (e.g., corn starch, lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silicon dioxide); disintegrants (e.g., sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). If desired, tablets may be coated using suitable methods and coating materials, such as OPADRY available from Colorcon, West Point, Pa. TM Film coating systems (eg, OPADRY TM OY, OYC, Organic Enteric OY-P, Aqueous Enteric OY-A, OY-PM and OPADRY TMWhite, 32K18400). Liquid preparations for oral administration may be in the form of solutions, syrups or suspensions. Liquid preparations may be prepared by conventional methods with pharmaceutically acceptable additives such as: suspending agents (e.g., sorbitol syrup, methylcellulose or hydrogenated edible fats); emulsifiers (e.g., lecithin or gum arabic); non-aqueous carriers (e.g., almond oil, oily esters or ethanol); and preservatives (e.g., methyl or propyl paraben or sorbic acid).

[0098] Granulation techniques are well known in the pharmaceutical art and are used to modify a starting powder or other particulate material of an active ingredient. The powder is usually mixed with a binder material to form larger permanent free-flowing agglomerates or granules - known as "granulation". For example, a "wet" granulation process using a solvent is generally characterized in that the powder is mixed with a binder material and moistened with water or an organic solvent under certain conditions to form a wet granular mass, from which the solvent must then evaporate.

[0099] Melt granulation is generally to use a material that is solid or semisolid at room temperature (i.e., having a relatively low softening or melting point range) to promote the granulation of a powder or other material, essentially without the addition of water or other liquid solvents. When heated to a temperature within the melting point range, the low melting solid liquefies to serve as a binder or granulation medium. The liquefied solid diffuses the liquefied solid itself over the surface of the powder material in contact with it, and forms a solid particulate material when cooled, wherein the initial material is combined together. The resulting melt granulation can then be provided to a tablet press or encapsulated to prepare an oral dosage form. Melt granulation improves the dissolution rate and bioavailability of an active substance (i.e., a drug) by forming a solid dispersion or a solid solution.

[0100] U.S. Patent No. 5,169,645 discloses directly compressible wax-containing particles with improved flow properties. When the wax is blended with certain flow-improving additives in a melt, and then the blend is cooled and granulated, the particles are obtained. In certain embodiments, only the wax itself is melted in the melt combination of the wax (or multiples) and the additive (or multiples), and in other cases, both the wax (or multiples) and the additive (or multiples) are melted.

[0101] The invention also includes multilayer tablets comprising a layer providing for delayed release of one or more compounds of the invention and another layer providing for immediate release of a drug for treating a disease or condition contemplated by the invention. Using wax / pH sensitive polymer mixtures, gastro-insoluble compositions can be obtained in which the active ingredient is trapped, ensuring its delayed release.

[0102] Parenteral administration

[0103] As used herein, "parenteral administration" of a pharmaceutical composition includes any route of administration characterized by physical disruption of a subject's tissue and administration of the pharmaceutical composition through a breach in the tissue. Thus, parenteral administration includes, but is not limited to, administration of the pharmaceutical composition by injection of the composition, application of the composition through a surgical incision, application of the composition through tissue penetration of a non-surgical wound, and the like. In particular, parenteral administration is contemplated to include, but is not limited to, subcutaneous, intravenous, intraperitoneal, intramuscular, intrasternal injection, and renal dialysis infusion techniques.

[0104] The preparation of the pharmaceutical composition suitable for parenteral administration comprises an active ingredient combined with a pharmaceutically acceptable carrier such as sterile water or sterile isotonic saline. Such a preparation can be prepared, packaged or sold in a form suitable for bolus administration or continuous administration. Injectable preparations can be prepared, packaged or sold in unit dosage form, such as in ampoules or multi-dose containers containing preservatives. Preparations for parenteral administration include but are not limited to suspensions, solutions, emulsions in oily or aqueous carriers, pastes and implantable sustained release or biodegradable preparations. Such a preparation may further include one or more additional ingredients, including but not limited to suspending agents, stabilizers or dispersants. In one embodiment of a preparation for parenteral administration, the active ingredient is provided in a dry (i.e., powder or granule) form for reconstitution with a suitable carrier (e.g., sterile pyrogen-free water) before parenteral administration of the reconstructed composition.

[0105] Pharmaceutical compositions can be prepared, packaged or sold in the form of sterile injectable aqueous or oily suspensions or solutions. The suspensions or solutions can be prepared according to known techniques and, in addition to the active ingredient, may also contain additional ingredients such as dispersants, wetting agents or suspending agents as described herein. Such sterile injectable preparations can be prepared using nontoxic parenterally acceptable diluents or solvents such as water or 1,3-butanediol. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic monoglycerides or diglycerides. Other preparations that can be used for parenteral administration include those containing active ingredients in microcrystalline form, in liposome preparations, or as components of biodegradable polymer systems. Compositions for sustained release or implantation may include pharmaceutically acceptable polymeric or hydrophobic materials such as emulsions, ion exchange resins, slightly soluble polymers or slightly soluble salts.

[0106] Controlled release formulations and drug delivery systems

[0107] In certain embodiments, the formulations of the invention may be, but are not limited to, short-term, rapid-offset, and controlled, such as sustained-release, extended-release, and pulsatile-release formulations.

[0108] The term sustained release is used in its conventional sense to refer to a pharmaceutical formulation that provides a gradual release of the drug over an extended period of time and, although not necessarily, can result in a substantially constant blood level of the drug over an extended period of time. The period of time can be as long as a month or more and should be a longer release than the same amount of the dose given in bolus form.

[0109] For sustained release, the compound can be formulated with a suitable polymer or hydrophobic material that provides the compound with sustained release properties. Thus, the compounds useful in the methods of the invention can be administered in the form of microparticles, for example by injection, or in the form of discs (wafers) or disks by implantation.

[0110] In one embodiment of the invention, the compounds of the invention are administered to a patient alone or in combination with another pharmaceutical agent using a sustained release formulation.

[0111] The term extended release is used herein in its conventional sense to refer to a drug formulation that provides initial release of the drug after some delay after drug administration, and although not required, may include a delay of from about 10 minutes up to about 12 hours.

[0112] The term pulsatile release is used herein in its conventional sense to refer to a drug formulation that provides release of the drug in a manner that produces a pulsatile plasma profile of the drug following administration of the drug.

[0113] The term immediate release is used in its conventional sense to refer to a drug formulation that provides for release of the drug immediately following drug administration.

[0114] As used herein, short-term refers to any time period after drug administration up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, about 10 minutes, or about 1 minute after drug administration, and any or all whole or partial increments thereof.

[0115] As used herein, rapid loss of efficacy refers to any time period after drug administration up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, about 10 minutes, or about 1 minute, and any or all whole or partial increments thereof.

[0116] Drug administration

[0117] The therapeutically effective amount or dosage of the compounds of the present invention depends on the age and weight of the patient, the patient's current medical condition, and the progression of the disease or condition contemplated by the present invention. A skilled person will be able to determine the appropriate dosage based on these and other factors.

[0118] The suitable dosage of the compound of the present invention can be about 0.01 mg to about 5,000 mg per day, such as about 0.1 mg to about 1,000 mg, for example, about 1 mg to about 500 mg, such as about 5 mg to about 250 mg per day. The dosage can be given in a single dose or multiple doses, for example 1 to 5 times or more per day. When multiple doses are used, the amount of each dose can be the same or different. For example, a dose of 1 mg per day can be given as two 0.5 mg doses, with an interval of about 12 hours between doses.

[0119] It should be understood that, in non-limiting examples, the amount of compound taken daily can be administered every day, every other day, every 2 days, every 3 days, every 4 days, or every 5 days. For example, if administered every other day, a daily 5 mg dose can be initiated on Monday, the first subsequent 5 mg dose of the day can be administered on Wednesday, the second subsequent 5 mg dose of the day can be administered on Friday, and so on.

[0120] In the event that the patient's condition does improve, administration of the inhibitor of the invention is optionally continued, at the physician's discretion; alternatively, the administered drug dose is temporarily reduced or temporarily stopped for a period of time (i.e., a "drug holiday"). The length of the drug holiday optionally varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. Dose reductions during a drug holiday include 10%-100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.

[0121] Once improvement in the patient's condition occurs, a maintenance dose is given if necessary. Subsequently, as a function of the disease or condition, the dosage or frequency or both given is reduced to a level that maintains the improved disease. In certain embodiments, the patient requires intermittent treatment on a long-term basis upon any recurrence of symptoms and / or infection.

[0122] The compounds used in the methods of the present invention can be formulated in unit dosage form. The term "unit dosage form" refers to physically discrete units suitable as unit doses for patients undergoing treatment, each unit containing a predetermined amount of active substance, calculated to produce the desired therapeutic effect, optionally combined with a suitable pharmaceutical carrier. The unit dosage form can be a single daily dose or one of multiple daily doses (e.g., about 1 to 5 or more times per day). When multiple daily doses are used, the unit dosage form of each dose can be the same or different.

[0123] The toxicity and therapeutic efficacy of such treatment regimens are optionally determined in experimental animals, including but not limited to determining the LD 50 (a dose lethal to 50% of the population) and ED 50 (the dose that is therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which is expressed as LD 50 and ED 50 The data obtained from animal studies are optionally used to formulate a dosage range for use in humans. The dosage of such compounds is preferably within the range that includes ED 50 The dosage may optionally vary within this range depending upon the dosage form employed and the route of administration utilized.

[0124] Those skilled in the art will recognize or be able to determine using only routine experimentation many equivalents to the specific procedures, embodiments, claims, and examples described herein. Such equivalents are considered to be within the scope of the present invention and are covered by the appended claims. For example, it should be understood that changes in reaction conditions, including but not limited to reaction times, reaction sizes / volumes, and experimental reagents, resulting from art-recognized alternatives and using only routine experimentation are within the scope of the present invention.

[0125] It should be understood that anywhere in the values ​​and ranges provided herein, the description of the range format is only for convenience and simplicity, and should not be interpreted as an inflexible limitation to the scope of the present invention. Therefore, all values ​​and ranges contained in these values ​​and ranges are intended to be included in the scope of the present invention. Moreover, the application also contemplates all values ​​falling within these ranges, as well as the upper or lower limits of a series of values. It should be considered that the description of the range specifically discloses all possible sub-ranges and each numerical value within the range, and when appropriate, the partial integer of the numerical value within the range. For example, it should be considered that the description of the range such as 1 to 6 has specifically disclosed sub-ranges such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., and each number within the range, for example, 1, 2, 2.7, 3, 4, 5, 5.3 and 6. Regardless of the breadth of the range, this applies.

[0126] The following examples further illustrate various aspects of the present invention. However, they are in no way limiting to the teachings or disclosures of the present invention described herein.

[0127] Example

[0128] The present invention will now be described with reference to the following examples. These examples are provided for illustrative purposes only, and the present invention should in no way be construed as being limited to these examples, but rather should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

[0129] Materials and methods

[0130] B16 B10 luciferase mouse melanoma cells were used for tumor administration in C57BL6 mice (subcutaneous or brain administration). Mouse monoclonal anti-PD-L1 (clone 10B5) (150 μg / mouse) was used in all experiments. PHY906 (500 mg / kg, twice daily) aqueous extract was used in the experiments.

[0131] In C57BL6 mice, 10 6 cells) or in the brain (10 per mouse 3 Cells) were implanted with B16B10 luciferase mouse melanoma cells. Treatment was started 6 days after tumor implantation. Mouse monoclonal anti-PD-L1 (clone 10B5) was used in all experiments (150 μg / mouse every 3 days). PHY906 aqueous extract was orally administered to mice at 500 mg / kg twice daily: subcutaneously for B16 tumors daily; for brain B16 tumors, starting on days 6-9 and 13-16. Tumor sizes of 150-300 mm were selected. 3 mice. By using the formula (length × width 2 ) / 2 was used to estimate the tumor volume. For luciferase imaging, 25 mg / kg of luciferin was injected into each mouse, and luciferase imaging was recorded using an IVIS imaging system.

[0132] Example 1: Preparation of herbal extracts

[0133] PHY906 consists of a traditional hot water extract of four herbs - Scutelleria baicalensis Georgi (S), Paeonia lactiflora (P), Glycyrrhiza uralensis (G), and Ziziphus jujuba (Z) (in a ratio of 3:2:2:2, respectively) - prepared under standard operating procedures. The extract contains a complex mixture of multiple phytochemicals with a variety of biological and pharmacological properties. At this time, it is not possible to identify a subset of relevant bioactive phytochemicals from the entire mixture. For this reason, we utilized high-level chemical and biological metrics to characterize the PHY906 product.

[0134] The raw materials of PHY906 were pre-selected to meet the strict specifications set by PhytoCeutica, which was accepted by Sun Ten Pharmaceuticals, a herbal medicine manufacturer in Taiwan, China. The PHY906 extract consists of more than 75% low molecular weight phytochemical compounds below 1000 amu, 10% macromolecular components (including proteins, nucleic acids, complex carbohydrates), and 5% water. In addition, 10% by weight of the excipient insoluble cellulose was added during the spray drying step in the manufacturing process. As detected by atomic absorption measurement, heavy metals (Pb, Hg, Cd, As) are all less than 0.5ppm, and mercury and cadmium are less than 0.03ppm. By LC-MS or GC-MS, the pesticide level (BHC, DDT, PCNB) is less than 0.2ppm. The total number of bacteria is 260cfu / g, and E. coli and Salmonella are not detected. More than 90% by weight of PHY906, excluding water content (5%) and insoluble starch excipients (10%), can be extracted again. The final PHY906 liquid extract (100 mg / ml) was stable at room temperature for 18 hours, and the properly stored bulk dry extract (vacuum packed, light-tight and 4°C) appeared to be stable for more than three years. More detailed information about PHY906 can be found in Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, Liu SH, Cheng YC, 2010, "The Four-Herb Chinese Medicine PHY906 Reduces Chemotherapy-Induced Gastrointestinal Toxicity", Sci. Transl. Med. 2(45):45ra59.

[0135] Example 2: Subcutaneous Melanoma Tumor Growth Inhibitory Activity of PHY906 Herbal Extract

[0136] The effects of PHY906 and anti-PD-L1 on the growth of B16 melanoma tumors implanted subcutaneously in B6 mice were investigated.

[0137] The combined effect of PHY906 and PD-L1 on the growth of B16 melanoma tumors implanted subcutaneously or in the brain of B6 mice was evaluated.

[0138] PHY906 (500 mg / kg twice daily, day 0 to day 5; Figure 1C ) and anti-PD-L1 (150 μg per animal, i.p., days 0 and 4; Figure 1D) showed significant (P<0.005) inhibition of B16 melanoma tumor growth implanted subcutaneously in B6 mice. Anti-PD-L1 plus PHY906 treatment showed greater inhibition of B16 tumor growth than anti-PD-L1 alone ( Figure 1A and 1D ).

[0139] Not all animals responded to anti-PD-L1 therapy ( Figure 1D However, anti-PD-L1 plus PHY906 combination treatment showed an inhibitory effect on the growth of B16 tumors in all animals ( Figure 1A and 1E Regarding animal toxicity, no weight loss and significant changes in blood cell counts (white blood cells, red blood cells, and platelets) were detected in any of the treatment groups ( Figure 1G ).

[0140] In conclusion, PHY906 alone showed anti-melanoma effects in vivo. Furthermore, anti-PD-L1 plus PHY906 combination therapy showed greater anti-melanoma activity than anti-PD-L1 alone.

[0141] Example 3: Brain-implanted melanoma tumor growth inhibitory activity of PHY906 herbal extract

[0142] The effects of PHY906 and anti-PD-L1 on the growth of B16 melanoma tumors implanted in the brain of B6 mice were investigated.

[0143] Brain metastasis is common in melanoma. Therefore, the combined effect of PHY906 and PD-L1 on the growth of B16 melanoma tumors implanted in the brain of B6 mice was explored. The results showed that PHY906 alone did not increase the survival time of animals with B16 tumor brain implants. In addition, anti-PD-L1 alone did prolong the survival of animals with B16 tumor brain implants. Luciferase measurements did show that anti-PD-L1 reduced the growth of B16 tumors in the brain ( Figure 2A-2E The combination of anti-PD-L1 plus PHY906 did not change the median survival of animals bearing B16 tumors in the brain compared with anti-PD-L1 alone ( Figure 2A Regarding animal toxicity, no body weight loss was detected in any treatment group ( Figure 2F In conclusion, PHY906 does not impair the anti-B16 melanoma activity of anti-PD-L1 in the brain.

[0144] Example 4: Subcutaneous Melanoma Tumor Growth Inhibitory Activity of PHY906 and S Herbal Extracts

[0145] The effects of isolated S, PHY906, and anti-PD-L1 on the growth of B16 melanoma tumors implanted subcutaneously in B6 mice were investigated.

[0146] The effects of PHY906 plus anti-PD-L1 and S plus anti-PD-L1 combination therapy on the growth of B16 melanoma tumors implanted subcutaneously in B6 mice were tested. Figure 3 As shown, S alone has an effect comparable to PHY906 in terms of enhancing the anti-tumor activity of anti-PD-L1 and enhancing the therapeutic activity of anti-PD-L1.

[0147] Example 5: Extract Fractionation Procedure

[0148] In certain embodiments of the invention, the extracts of the invention (including water extracts and other solvent extracts) can be further processed into isolated fractions, which can be used in the therapeutic methods of the invention. Non-limiting examples are as follows:

[0149] Solid phase extraction method

[0150] The herbal water extract or other solvent extract (1ml, 100mg / ml) was passed through DSC-18 SPE tube bed (weight 1 g). Bound chemicals were eluted using 1 ml of water, 10% ethanol, 30% ethanol, 50% ethanol, 70% ethanol and 100% ethanol sequentially. Different fractions were vacuum dried to form pellets. The dried pellets were reconstituted to 1 ml with water. The reconstituted solution was considered as "100 mg / ml equivalent" of the original herbal water extract input and used for further experiments.

[0151] Liquid chromatography-mass spectrometry (LC-MS)

[0152] Chromatographic separation was achieved on a ZORBAX-SBC18 column (100 mm × 2.1 mm inner diameter, 3.5 μm, Agilent, Palo Alto, CA). Mobile phase A was water containing 0.05% (v / v) formic acid, while mobile phase B was acetonitrile. The liquid flow rate was set at 0.3 mL / min and the column temperature was maintained at 30 °C. The mobile phase consisted of a linear gradient of 0.05% (v / v) formic acid (A) and acetonitrile (B). The chromatographic system used consisted of an Agilent 1200 HPLC series, including a binary pump (model G1312B), a vacuum degasser (model G1379B), an autosampler (model G1367C), and a column oven (model G1316B). The chromatography was performed by an Applied Biosystems Sciex 4000 A mass spectrometer (Applied Biosystems Sciex; Foster, CA) was used to detect a large number of chemicals. Data acquisition was performed by Analyst on a DELL computer. Software execution.

[0153] Example 6: B16 melanoma growth inhibitory activity of PHY906 and anti-PD-L1, anti-PD1 and anti-CTLA4 antibodies

[0154] By giving 500 mg / kg PHY906 twice daily ( Figures 6A-6D )、Anti-PD-L1( Fig. 6A , 150 μg / animal, once every 3 days), anti-PD1 ( Figure 6B / 6D, 150 μg / animal, once every 3 days), anti-CTLA4 ( Figure 6C The effects of PHY906 alone and in combination with anti-PD-L1, anti-PD1, and anti-CTLA4 antibodies on B16 melanoma in vivo were tested at 2 doses (1:1, 2:1, 3:1, 6:1, 1:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1

[0155] The combination of anti-PD-L1 and PHY906 was highly effective in impeding tumor growth in mouse models ( Fig. 6A ). The combination of anti-PD1 and PHY906 was also more effective than either alone. The combination of anti-CTLA4 and PHY906 did not appear to have a strong effect on inhibiting tumor growth, however, the combination of anti-PD1, anti-CTLA4 and PHY906 showed a very strong effect, completely inhibiting the growth of tumors in some subjects.

[0156] Example 7: Tumor inhibitory activity of PHY906 and anti-PD1 antibody on Hepa 1-6 mouse hepatic adenocarcinoma

[0157] The effect of PHY906 alone and in combination with anti-PD1 antibody on Hepa 1-6 mouse hepatic adenocarcinoma tumors in vivo was tested by administering: 500 mg / kg PHY906 twice daily, 70 or 200 μg of anti-PD1 antibody once per mouse at the beginning of the experiment, or a combination of both treatments. It was found that single treatment with PHY906 or anti-PD1 hindered tumor growth when compared to mice treated with placebo. In addition, treatment with a combination of PHY906 and anti-PD1 produced a stronger tumor inhibitory effect. The experiment was repeated and the efficacy of the combination treatment was reproducible.

[0158] Example 8: CMT-167 non-small cell lung cancer tumor inhibitory activity of PHY906 and anti-PD1 antibody

[0159] The effect of PHY906 alone and in combination with anti-PD1 antibody on CMT-167 non-small cell lung cancer tumors in vivo was tested by administering: 500 mg / kg PHY906 twice daily, 200 μg anti-PD1 antibody once per mouse at the beginning of the experiment, or a combination of both treatments. It was found that while both treatments hindered tumor growth alone, the combination of PHY906 and anti-PD1 showed a much greater inhibitory effect on the growth of non-small cell lung cancer tumors.

[0160] The disclosure of each patent, patent application and publication cited herein is incorporated herein by reference in its entirety. Although the present invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of the present invention may be devised by other skilled in the art without departing from the true spirit and scope of the present invention. The appended claims are intended to be interpreted as including all such embodiments and equivalent variations.

Claims

1. A kit comprising one or more immune checkpoint inhibitors and at least one herbal composition selected from the group consisting of: (a) an herbal extract of Scutellaria baicalensis (S), a fraction thereof or any active chemical substance present in said herbal extract or a fraction thereof; (b) herbal extract PHY906, a fraction thereof or any active chemical substance present in the herbal extract or fraction thereof, the herbal extract PHY906 comprising herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Ziziphus jujuba (Z); (c) an herbal extract comprising an extract of S, a fraction thereof or any active chemical substance present in said herbal extract or a fraction thereof; and (d) an herbal extract comprising a combination of S, G, P and Z, a fraction thereof or any active chemical substance present in the herbal extract or a fraction thereof.

2. The kit of claim 1, wherein (a) or (c) further comprises an herbal extract, a portion thereof, or any active chemical substance present in the herbal extract or a portion thereof, wherein the herbal extract is from at least one herb selected from Licorice (G), Peony (P) and Jujube (Z).

3. The kit of claim 1, wherein the immune checkpoint inhibitor is selected from anti-PD1, anti-PD-L1 and anti-CTLA4.

4. The kit of claim 3, wherein the immune checkpoint inhibitor is selected from ipilimumab, pembrolizumab, nivolumab, durvalumab, and atezolizumab.

5. The kit of claim 1, further comprising one or more pharmaceutically acceptable carriers.

6. A method of treating cancer in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of at least one herbal composition selected from: (a) an herbal extract of Scutellaria baicalensis (S), a fraction thereof or any active chemical substance present in said herbal extract or a fraction thereof; (b) herbal extract PHY906, a fraction thereof or any active chemical substance present in the herbal extract or fraction thereof, the herbal extract PHY906 comprising herbal extracts of Scutellaria baicalensis (S), Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Ziziphus jujuba (Z); (c) an herbal extract comprising an extract of S, a fraction thereof or any active chemical substance present in said herbal extract or a fraction thereof; and (d) herbal extracts comprising a combination of S, G, P and Z, fractions thereof or any active chemical substance present in said herbal extracts or fractions thereof; wherein the subject is also administered one or more immune checkpoint inhibitors, The cancer is at least one selected from melanoma, non-small cell lung cancer, renal cell carcinoma, liver cancer, colon cancer, urothelial bladder cancer and pancreatic cancer.

7. The method of claim 6, wherein (a) or (c) further comprises an herbal extract, a portion thereof, or any active chemical substance present in the herbal extract or a portion thereof, wherein the herbal extract is from at least one herb selected from the group consisting of Glycyrrhiza uralensis (G), Paeonia lactiflora (P) and Jujube (Z).

8. The method of claim 6, wherein the immune checkpoint inhibitor is selected from anti-PD1, anti-PD-L1 and anti-CTLA4.

9. The method of claim 8, wherein the immune checkpoint inhibitor is selected from ipilimumab, pembrolizumab, nivolumab, durvalumab, and atezolizumab.

10. The method of claim 6 or 7, wherein the therapeutically effective amount of the herbal composition minimizes or eliminates gastrointestinal side effects of one or more of the immune checkpoint inhibitors, the gastrointestinal side effects selected from nausea, vomiting, fatigue, colitis and diarrhea.

11. The method of claim 6 or 7, wherein the cancer is melanoma.

12. The method of claim 6 or 7, wherein the herbal composition is administered orally to the subject.

13. The method of claim 12, wherein the herbal composition is orally administered to the subject in a form selected from the group consisting of pills, tablets, capsules, soups, teas, concentrates, lozenges, liquids, drops, and gelatin capsules.

14. The method of claim 6 or 7, wherein the therapeutically effective amount of the herbal composition is from about 20 mg / day to about 2 g / day.

15. The method of claim 14, wherein the therapeutically effective amount of the herbal composition is about 1,600 mg / day.

16. The method of claim 6 or 7, wherein the herbal composition is administered twice daily.

17. The method of claim 16, wherein the herbal composition is administered twice daily for about one to about two weeks, followed by a break in treatment for at least one week.

18. The method of claim 6 or 7, wherein the herbal composition is administered at a time selected from before, simultaneously with, and after administration of the one or more immune checkpoint inhibitors to the subject.

19. The method of claim 6, wherein the subject is a mammal.

20. The method of claim 19, wherein the mammal is a human.